Thursday, December 30, 2010 2:04:03 AM
The stock price, by itself, also doesn't determine whether or not you are a winner in your evaluation of the company, as that is always based on the results of your evaluation seen in your choices to buy and sell, and the timing of those choices.
If you buy low, and sell high... you win the market battle... which is simple enough, and obvious enough.
In my book, ATNY, the company, is a winner... because of the FACTS re what the company has and what the company is doing, that I see has value. Solid DD proved to me it was a solid company, with good management, and clearly contained risks, and it was quite clearly undervalued by the market when I bought it... and since then it it seems the market agrees.
In my books, ATNY was also a winner on the trade... because of the FACTS re the choices that I made in buying and selling... which are documented here, well enough... that are MORE about the choices made and the timing of them, than about the company.
Split adjusted, from $1 to $7 in less than a year is not bad.
Of course, between then and now, in the last year, you also could have bought it at $7 and sold it recently for a lot less than that. I'm sure many people did just that.
That people DO make bad choices in timing their trades... doesn't mean the company isn't a winner... or that the company is an evil doer perpetrating a fraud.
Those who blame anyone other than themselves for their own bad choices in timing investments... aren't always wrong about their being others in the market who are behaving badly. That doesn't mean anyone who loses money on a trade... is a victim of a scam.
ATNY is pretty clearly NOT a scam... rather than a trusted supplier of components for top secret government programs...
So, while NOT being a scam, if they can ALSO find a way to make MONEY and turn a profit from being a trusted supplier of components for top secret government programs... they'll prove to be a winner... whether you ever make a dime trading the stock or not.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM